BioWorld

Oct. 11, 2010

Reading the Tea Leaves for Interferon's Future in HCV

Last week's complete response letter for Human Genome Sciences Inc. and Novartis AG's Zalbin (albinterferon alfa-2b) came as no surprise given the hepatitis C drug's history. Read More

Money Raised Year to Date

More Pharma-Dumped Assets Coming Back Home to Biotech

When the Going Gets Tough, the Tough Reverse Stock Split

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

Phase I Clinical Trials Update: September 2010

FDA Approvals in September

Phase II Clinical Trials Update: September 2010

Phase III Clinical Trials Update: September 2010

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Non-U.S. Clinical Trials & Regulatory Actions: Sept. 2010

FDA Submissions, Approvals & Other Actions: Sept. 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 3, 2025.

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

BioWorld

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...

ASCO 2025: Verastem has positive cancer data but stock sags

BioWorld

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...

Pan-cancer proteome atlas reveals new biomarkers and targets

BioWorld Science

An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...